 SOMERVILLE, Mass., Sept. 07, 2021 GLOBE NEWSWIRE -- Finch Therapeutics Group, Inc. Finch or Finch Therapeutics Nasdaq: FNCH, a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available on Monday, September 13, 2021 at 7:00 am ET. 